Floatz logo

Ibrutinib

Colorectal Carcinoma

H. Lee Moffitt Cancer Center and Research InstituteSmall moleculePhase 1/2Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
73/ 100

Competitive context

161 Active assets in the Colorectal Carcinoma cohort.

Asset / SponsorPhaseRating
TIPIRACIL
Mayo Clinic
Phase 2BBB
FLUOROURACILUM
City of Hope Medical Center
Phase 4BB
Eloxatin
First Affiliated Hospital of Zhejiang University
Phase 4BB
MITOMYCIN C
City of Hope Medical Center
Phase 3BB
Capecitabine
First Affiliated Hospital of Zhejiang University
Phase 4BB

View all 50 →

Same molecule, other indications

Ibrutinib is also rated in:

lymphoid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Waldenstrom macroglobulinemiaDormant
BB
Indicative ·
70 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →